Skip to content
DataLookout
Menu

NCT07278362

Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance

StatusRecruiting
PhasePhase 4
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened Show 4 more changesShow less
    • Start date: Aug 31, 2026 to Nov 30, 2026
    • Eligibility criteria shortened, about 25 words
    • Secondary endpoints: details revised at 8 of 8 entries
    • Site details revised at 2 of 2 sites
  2. Notable Start date: May 31, 2026 to Aug 31, 2026v3
  3. Notable Start date: Feb 2026 to May 31, 2026
    • Primary completion date: Feb 2031 to May 31, 2031
    • Study completion date: Feb 2032 to May 31, 2032
    v2
  4. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Proportion of Participants with Disease Progression Within 12 Months After Initiating TRT
Timeframe: 12 months

Secondary (8)

Mean Change in Serum PSA Levels (ng/mL) from Baseline to 12 Months
Change in Total Testosterone Levels (ng/dL) from Baseline to 12 Months
Mean Change in Hematocrit Levels (%) from Baseline to 12 Months
Mean Change in Prostate Volume (mL) as measured by mpMRI from Baseline to 12 Months
Mean Change in EPIC-26 Scores from Baseline to 12 Months
Show 3 moreShow less
Mean Change in SF-12 Scores from Baseline to 12 Months
Mean Change in Aging Male's Symptoms Score (AMS) from Baseline to 12 Months
Progression-Free Survival (PFS) from Baseline to 5 Years

Arms and interventions

Testosterone cypionateExperimental

Participants will self-inject 100mg of testosterone cypionate once per week for 12 months

Drugs: Testosterone cypionate

Sites

2 sites in 1 country